Boris Kallmann

2.2k total citations · 1 hit paper
28 papers, 1.5k citations indexed

About

Boris Kallmann is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Boris Kallmann has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 6 papers in Rheumatology and 5 papers in Oncology. Recurrent topics in Boris Kallmann's work include Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Boris Kallmann is often cited by papers focused on Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Boris Kallmann collaborates with scholars based in Germany, Switzerland and United States. Boris Kallmann's co-authors include Peter Rieckmann, Klaus V. Toyka, Oliver Grauer, Tania Kümpfel, Claudia Trenkwalder, M. Gottschalk, Peter Flachenecker, Hubert Kolb, Martin Stangel and Iris‐Katharina Penner and has published in prestigious journals such as Brain, Neurology and Diabetes.

In The Last Decade

Boris Kallmann

26 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters

2002 505 citations Boris Kallmann, Peter Rieckmann et al. Multiple Sclerosis Journal profile →

Peers

Countries citing papers authored by Boris Kallmann

Since Specialization

Citations

This map shows the geographic impact of Boris Kallmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Kallmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Kallmann more than expected).

Fields of papers citing papers by Boris Kallmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Kallmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Kallmann. The network helps show where Boris Kallmann may publish in the future.

Co-authorship network of co-authors of Boris Kallmann

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Kallmann. A scholar is included among the top collaborators of Boris Kallmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Kallmann. Boris Kallmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program 2024 ·Neurology and Therapy ·Matthias Schwab, Andrew Chan, (unknown), Boris Kallmann, Dieter Pöhlau, Joachim Richter, (unknown), Christoph Grothe	0
2	Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4 2022 ·Expert Opinion on Pharmacotherapy ·Sven G. Meuth, Antonios Bayas, Boris Kallmann, Ralf A. Linker, Peter Rieckmann, Mike P. Wattjes, Mathias Mäurer, Christoph Kleinschnitz	21
3	Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion 2020 ·Expert Opinion on Pharmacotherapy ·Sven G. Meuth, Antonios Bayas, Boris Kallmann, Christoph Kleinschnitz, Ralf A. Linker, Peter Rieckmann, Mathias Mäurer	10
4	Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study 2019 ·Therapeutic Advances in Neurological Disorders ·Boris Kallmann, Klaus Tiel‐Wilck, Jennifer S. Kullmann, (unknown), Andrew Chan	24
5	Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study 2018 ·Journal of Neurology ·Konstantin Huhn, Antonios Bayas, (unknown), Benedikt Frank, Kathrin Gerbershagen, Kerstin Hellwig, Boris Kallmann, Christoph Kleinschnitz, Ingo Kleiter, De-Hyung Lee, Volker Limmroth, Mathias Mäurer, Sven G. Meuth, Peter Rieckmann, Tobias Ruck, Ralf Gold, Ralf A. Linker	29
6	Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study 2015 ·Expert Opinion on Drug Delivery ·Antonios Bayas, Jean‐Christophe Ouallet, Boris Kallmann, Raymond Hupperts, (unknown), (unknown)	38
7	„Time is brain“ bei der schubförmigen Multiplen Sklerose 2015 ·Der Nervenarzt ·Ralf A. Linker, Boris Kallmann, Christoph Kleinschnitz, Peter Rieckmann, M. Mäurer, Stefan Schwab	5
8	Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model 2014 ·Therapeutic Advances in Neurological Disorders ·Martin Stangel, Iris‐Katharina Penner, Boris Kallmann, Carsten Lukas, Bernd C. Kieseier	131
9	Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose 2013 ·Aktuelle Neurologie ·Martin Stangel, Iris‐Katharina Penner, Boris Kallmann, Carsten Lukas, B. C. Kieseier, Ralf Gold	6
10	Isolation of Brucella melitensis from a patient with hearing loss 2006 ·European Journal of Clinical Microbiology & Infectious Diseases ·(unknown), Boris Kallmann, (unknown), Robert Mlynski, Karsten Nöckler, Oliver Kurzai, Matthias Frosch, Marianne Abele‐Horn	11
11	Neue Therapieansätze bei Multipler Sklerose 2005 ·Nervenheilkunde ·Boris Kallmann, (unknown)	0
12	Inflammation in multiple sclerosis: the good, the bad, and the complex 2002 ·The Lancet Neurology ·Gianvito Martino, Luciano Adorini, Peter Rieckmann, Jan Hillert, Boris Kallmann, Gıancarlo Comı, Massimo Filippi	108
13	Human cerebral endothelial cells are a potential source for bioactive BDNF 2002 ·Cytokine ·Antonios Bayas, Vera Hummel, Boris Kallmann, (unknown), K. V. Toyka, Peter Rieckmann	39
14	Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules 2001 ·Journal of Neuropathology & Experimental Neurology ·Vera Hummel, Boris Kallmann, Sabine Wagner, (unknown), Antonios Bayas, J.-C. Tonn, Etty Benveniste, Klaus V. Toyka, Peter Rieckmann	65
15	Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1 2000 ·Brain ·Boris Kallmann	90
16	Cytokine secretion patterns in twins discordant for Type I diabetes 1999 ·Diabetologia ·Boris Kallmann, E. F. Lampeter, Pejman Hanifi-Moghaddam, Mohammed I. Hawa, R. D. G. Leslie, Hubert Kolb	40
17	Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis 1998 ·Multiple Sclerosis Journal ·Peter Rieckmann, (unknown), (unknown), Boris Kallmann, K. Felgenhauer	39
18	Systemic Bias of Cytokine Production Toward Cell-Mediated Immune Regulation in IDDM and Toward Humoral Immunity in Graves' Disease 1997 ·Diabetes ·Boris Kallmann, (unknown), (unknown), Joachim Feldkamp, Jörg Bertrams, F. A. Gries, E. F. Lampeter, Hubert Kolb	101
19	Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide 1992 ·Life Sciences ·Boris Kallmann, Volker Burkart, K D Kröncke, V. Kolb‐Bachofen, Hubert Kolb	83
20	Cyclosporin A protects pancreatic islet cells from nitric oxide‐dependent macrophage cytotoxicity 1992 ·FEBS Letters ·Volker Burkart, Yoichiro Imai, Boris Kallmann, Hubert Kolb	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact